124 related articles for article (PubMed ID: 32809160)
41. Solitary pulmonary nodule evaluation in regions endemic for infectious diseases: Do regional variations impact the effectiveness of fluorodeoxyglucose positron emission tomography/computed tomography.
Purandare NC; Pramesh CS; Agarwal JP; Agrawal A; Shah S; Prabhash K; Karimundackal G; Jiwnani S; Tandon S; Rangarajan V
Indian J Cancer; 2017; 54(1):271-275. PubMed ID: 29199704
[TBL] [Abstract][Full Text] [Related]
42. Talc Pleurodesis With Intense 18F-FDG Activity But No 68Ga-DOTA-TATE Activity on PET/CT.
Papadakis GZ; Millo C; Bagci U; Patronas NJ; Stratakis CA
Clin Nucl Med; 2015 Oct; 40(10):819-20. PubMed ID: 26018715
[TBL] [Abstract][Full Text] [Related]
43. The Value of 18F-FDG PET/CT in the Diagnosis of Tuberculous Pleurisy and in the Differential Diagnosis between Tuberculous Pleurisy and Pleural Metastasis from Lung Adenocarcinoma.
Du X; Zhu F; Yu C
Contrast Media Mol Imaging; 2022; 2022():4082291. PubMed ID: 35965614
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
45. Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions.
Nose H; Otsuka H; Otomi Y; Terazawa K; Takao S; Iwamoto S; Harada M
J Med Invest; 2013; 60(3-4):184-90. PubMed ID: 24190034
[TBL] [Abstract][Full Text] [Related]
46. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
47. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients.
Barrio M; Czernin J; Yeh MW; Palma Diaz MF; Gupta P; Allen-Auerbach M; Schiepers C; Herrmann K
Nucl Med Commun; 2016 Dec; 37(12):1290-1296. PubMed ID: 27612034
[TBL] [Abstract][Full Text] [Related]
48. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
[TBL] [Abstract][Full Text] [Related]
49. 18F-FDG uptake in the normal appendix in adults: PET/CT evaluation.
Silman C; Matsumoto S; Ono A; Kiyonaga M; Otsuka K
Ann Nucl Med; 2019 Apr; 33(4):265-268. PubMed ID: 30652242
[TBL] [Abstract][Full Text] [Related]
50. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
[TBL] [Abstract][Full Text] [Related]
51. Correlation Between
Yu P; Lei J; Xu B; Wang R; Shen Z; Tian J
Acad Radiol; 2020 May; 27(5):682-688. PubMed ID: 31311773
[TBL] [Abstract][Full Text] [Related]
52. Indeterminate pleural metastasis on contrast-enhanced chest CT in non-small cell lung cancer: improved differential diagnosis with (18)F-FDG PET/CT.
Jung MY; Chong A; Seon HJ; Choi S; Kim YH; Shin SS; Kim JW; Bom HS
Ann Nucl Med; 2012 May; 26(4):327-36. PubMed ID: 22350956
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.
Duysinx B; Nguyen D; Louis R; Cataldo D; Belhocine T; Bartsch P; Bury T
Chest; 2004 Feb; 125(2):489-93. PubMed ID: 14769729
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
55. Pictorial review of
Ishibashi M; Tanabe Y; Fujii S; Ogawa T
Ann Nucl Med; 2017 Jul; 31(6):437-453. PubMed ID: 28585058
[TBL] [Abstract][Full Text] [Related]
56. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
Pilling J; Dartnell JA; Lang-Lazdunski L
Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
[TBL] [Abstract][Full Text] [Related]
57. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
58. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
59. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial.
Luh KT; Yang PC; Kuo SH; Chang DB; Yu CJ; Lee LN
Cancer; 1992 Feb; 69(3):674-9. PubMed ID: 1309678
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of pretreatment volume-based quantitative
Kitajima K; Doi H; Kuribayashi K; Hashimoto M; Tsuchitani T; Tanooka M; Fukushima K; Nakano T; Hasegawa S; Hirota S
Eur J Radiol; 2017 Jan; 86():176-183. PubMed ID: 28027744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
